Filana Therapeutics (FLNA) Non-Current Deffered Revenue (2010 - 2013)
Filana Therapeutics (FLNA) posted quarterly Non-Current Deffered Revenue of $27.4 million for Q3 2013, down 6.67% quarter-over-quarter from $29.4 million in Q2 2013.
Filana Therapeutics (FLNA) Non-Current Deffered Revenue (2010 - 2013) Analysis & Trends
Filana Therapeutics' Non-Current Deffered Revenue history runs 4 years deep, the most recent figure standing at $27.4 million for Q3 2013.
- In Q3 2013, Non-Current Deffered Revenue changed N/A year-over-year to $27.4 million; the TTM figure through Sep 2013 stood at $27.4 million (changed N/A YoY), while the FY2012 annual figure was $33.3 million, down 18.54% from the prior year.
- Non-Current Deffered Revenue for Q3 2013 stood at $27.4 million, down from $29.4 million in the prior quarter.
- The five-year high for Non-Current Deffered Revenue was $51.8 million in Q4 2010, with the low at $27.4 million in Q3 2013.
- The 4-year median for Non-Current Deffered Revenue is $38.1 million (2012), against an average of $38.0 million.
- The sharpest annual moves came in 2011 and 2013: Non-Current Deffered Revenue fell 21.05% in 2011, then fell 17.86% in 2013.
- Filana Therapeutics' Non-Current Deffered Revenue stood at $51.8 million in 2010, then dropped by 21.05% to $40.9 million in 2011, then declined by 18.54% to $33.3 million in 2012, then retreated by 17.65% to $27.4 million in 2013.
- Business Quant data shows FLNA's Non-Current Deffered Revenue at $27.4 million in Q3 2013, $29.4 million in Q2 2013, and $31.3 million in Q1 2013.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 220.40 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 147.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Filana Therapeutics | 46.00 Mn | 46.00 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2013 | 27.41 Mn |
| Jun 30, 2013 | 29.37 Mn |
| Mar 31, 2013 | 31.33 Mn |
| Dec 31, 2012 | 33.29 Mn |
| Mar 31, 2012 | 38.14 Mn |
| Dec 31, 2011 | 40.86 Mn |
| Sep 30, 2011 | 43.59 Mn |
| Jun 30, 2011 | 46.31 Mn |
| Dec 31, 2010 | 51.76 Mn |